Nuvation Bio Inc. (NUVB) Financials, Dividends & Stock Info
Explore comprehensive financial data for Nuvation Bio Inc., provided completely free. Analyze revenue, net income, profit margins, dividend history, and key financial ratios to make informed investment decisions.
Data as of (572 days ago)|Source: SEC EDGAR
The information on this page is for informational purposes only and does not constitute investment advice, financial advice, or any recommendation. Billiver does not recommend buying, selling, or holding any security. Past performance is not indicative of future results.
Data may be delayed and accuracy is not guaranteed. All investment decisions are solely your responsibility. Verify information independently and consult a qualified financial advisor before investing. About · Methodology
Nuvation Bio Inc. (NUVB) is a pharmaceuticals company. The company reports annual revenue of $8M and net loss of $568M.
Nuvation Bio Inc. Key Financials
Data from SEC EDGAR filings. TTM = Trailing Twelve Months.
Nuvation Bio Inc. Financial Health ScoreFY2025
Below average; significant concerns in multiple areas
+27 pts YoYThis Financial Health Score is a proprietary metric calculated from SEC EDGAR filings for educational and informational purposes only. It does not constitute investment advice or a recommendation to buy or sell any security. Results vary significantly by industry. Conduct your own research before making investment decisions.
Data Highlights
- Altman Z-Score -1.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Nuvation Bio Inc. Recent Events
Source: SEC EDGAR 8-K Filings
5-Year Revenue & Net Income Trend
Chart shows fiscal year data from SEC EDGAR filings. Hover over data points for details.
As of FY2025 · SEC 10-K · Updated Mar 29, 2026
About Nuvation Bio Inc.
- Industry
- Pharmaceuticals
Valuation
Valuation Data UnavailablePrice-based valuation metrics (P/E, P/B) require real-time stock price data which is not included in SEC filings.
Benjamin Graham: Graham recommended P/E ratio not exceed 15 for reasonable valuation. Understanding valuation metrics
Profitability
Profitability Data Under ReviewProfitability metrics are being verified. Some SEC filing data may require additional validation.
Warren Buffett: Buffett looks for consistent ROE above 20% as a sign of competitive advantage. How to evaluate profitability
Financial Health
Balance Sheet Data LimitedInsufficient data to assess financial health.
Peter Lynch: Lynch: normal balance sheet has 75% equity, 25% debt. Understanding financial health
Dividend
Dividend Data UnavailableDividend yield data is not available from SEC filings. Check the company's investor relations page for dividend information.
As of FY2025 · SEC 10-K · Updated Mar 29, 2026
Nuvation Bio Inc. 6-Year Revenue, Profit & Cash Flow History
Annual Financials
FY2025 - FY2020| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $62.9M(+699.0%) | $7.9M | $0 | - | - | - |
| Net Income | $-204,627,000(+64.0%) | $-567,939,000(-649.2%) | $-75,802,000(+27.3%) | $-104,199,000(-20.0%) | $-86,848,000(-108.5%) | $-41,659,000 |
| Total Assets | $594.8M | $540.6M | $621.5M | $672.1M | $776.2M | $221.8M |
| Total Debt | $47.2M | - | - | - | - | - |
| Total Equity | $305.7M | $463.8M | $605.1M | $655.1M | $746.0M | $215.1M |
| Profit Margin | -325.3% | -7213.8% | - | - | - | - |
| ROE | -66.9% | -122.5% | -12.5% | -15.9% | -11.6% | -19.4% |
| ROA | -34.4% | -105.0% | -12.2% | -15.5% | -11.2% | -18.8% |
Quarterly Financials
Last 8 quarters| Metric | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.1M | $13.1M | $4.8M | $3.1M | $727,000 | $1.4M | $0 | $0 |
| Net Income | $-53,236,000 | $-55,792,000 | $-59,007,000 | $-53,236,000 | $-41,210,000 | $-462,492,000 | $-14,792,000 | $-19,649,000 |
| Total Assets | $594.8M | $601.6M | $647.2M | $492.5M | $571.6M | $594.8M | $613.1M | $630.9M |
As of FY2025 · SEC 10-K · Updated Mar 29, 2026
Insider Trading
Source: SEC EDGAR Form 4 filings. Only purchase (P) and sale (S) transactions shown.
Nuvation Bio Inc. Free Cash Flow & Dividend Coverage
Cash Flow History
FY2020 - FY2025| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating CF | -$36.5M | -$68.2M | -$96.1M | -$68.0M | -$130.4M | -$173.4M |
| CapEx | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| FCF Margin | - | - | - | - | - | - |
Source: SEC EDGAR 10-K filings. FCF = Operating Cash Flow - Capital Expenditures. Free cash flow guide
As of FY2025 · SEC 10-K · Updated Mar 29, 2026
Nuvation Bio Inc. Risk Factors
Company-disclosed SEC risk factors
Risk factors are disclosed by the company in its SEC Form 10-K, Item 1A. Billiver does not classify or summarize company-specific legal, operational, financial, or market risks here.
Sector context: Health Care. This is not a Billiver risk assessment for NUVB.
Source note: the SEC Form 10-K includes Item 1A, "Risk Factors." The full risk-factor text should be read from the company’s own SEC filing.
Nuvation Bio Inc. FAQ
What is Nuvation Bio Inc.'s annual revenue?
Nuvation Bio Inc. (NUVB) reported $8 million in trailing twelve-month (TTM) revenue. This financial data is compiled from SEC EDGAR 10-K filings.
Does Nuvation Bio Inc. pay dividends?
No, Nuvation Bio Inc. (NUVB) does not currently pay dividends to shareholders.
What is Nuvation Bio Inc.'s financial health score?
Nuvation Bio Inc. has a financial health score of 59/100 (Grade: D), evaluating profitability, solvency, liquidity, and growth based on SEC EDGAR data.
How many years of Nuvation Bio Inc. financial data are available?
6 years of financial data are available for Nuvation Bio Inc. from FY2020 to FY2025. All figures are compiled from SEC EDGAR 10-K filings.